Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer | Zendy

Kumar Prabhash | Zendy; Vijay Patil | Zendy; Vanita Noronha | Zendy; Amit Joshi | Zendy; Anuradha Chougule | Zendy; Atanu Bhattacharjee | Zendy; Alok Goel | Zendy; Vikas Talreja | Zendy; Nandini Me | Zendy; Anant Ramaswamy | Zendy; Ashay Karpe | Zendy; Nikhil Pande | Zendy; Arun Chandrasekharan | Zendy; Abhishek Mahajan | Zendy; Amit Janu | Zendy; Nilendu Purandare | Zendy

Open Access

Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer

Author(s) -

Kumar Prabhash,

Vijay Patil,

Vanita Noronha,

Amit Joshi,

Anuradha Chougule,

Atanu Bhattacharjee,

Alok Goel,

Vikas Talreja,

Nandini Me,

Anant Ramaswamy,

Ashay Karpe,

Nikhil Pande,

Arun Chandrasekharan,

Abhishek Mahajan,

Amit Janu,

Nilendu Purandare

Publication year - 2019

Publication title -

cancer research statistics and treatment

Language(s) - English

Resource type - Journals

eISSN - 2590-3233

pISSN - 2590-3225

DOI - 10.4103/crst.crst_17_19

Subject(s) - pemetrexed , gefitinib , carboplatin , medicine , epidermal growth factor receptor , oncology , randomization , cetuximab , randomized controlled trial , chemotherapy , cancer , cisplatin , colorectal cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research